- Home
- CANF vs QMCO Comparison
CANF vs QMCO Comparison
Compare CANF & QMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- QMCO
- Stock Information
- Founded
- CANF 1994
- QMCO 1980
- Country
- CANF Israel
- QMCO United States
- Employees
- CANF N/A
- QMCO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- QMCO Electronic Components
- Sector
- CANF Health Care
- QMCO Technology
- Exchange
- CANF Nasdaq
- QMCO Nasdaq
- Market Cap
- CANF 9.6M
- QMCO 98.8M
- IPO Year
- CANF N/A
- QMCO N/A
- Fundamental
- Price
- CANF $0.65
- QMCO $8.45
- Analyst Decision
- CANF Strong Buy
- QMCO Hold
- Analyst Count
- CANF 2
- QMCO 2
- Target Price
- CANF $14.50
- QMCO $19.00
- AVG Volume (30 Days)
- CANF 162.7K
- QMCO 832.2K
- Earning Date
- CANF 08-26-2025
- QMCO 09-10-2025
- Dividend Yield
- CANF N/A
- QMCO N/A
- EPS Growth
- CANF N/A
- QMCO N/A
- EPS
- CANF N/A
- QMCO N/A
- Revenue
- CANF $560,000.00
- QMCO $266,079,000.00
- Revenue This Year
- CANF $461.72
- QMCO N/A
- Revenue Next Year
- CANF N/A
- QMCO $7.66
- P/E Ratio
- CANF N/A
- QMCO N/A
- Revenue Growth
- CANF N/A
- QMCO N/A
- 52 Week Low
- CANF $0.63
- QMCO $2.88
- 52 Week High
- CANF $3.12
- QMCO $90.64
- Technical
- Relative Strength Index (RSI)
- CANF 36.38
- QMCO 56.95
- Support Level
- CANF $0.64
- QMCO $7.07
- Resistance Level
- CANF $0.68
- QMCO $8.62
- Average True Range (ATR)
- CANF 0.02
- QMCO 0.48
- MACD
- CANF 0.01
- QMCO 0.15
- Stochastic Oscillator
- CANF 50.00
- QMCO 66.98
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About QMCO Quantum Corporation
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).